TY - JOUR
T1 - Cytokine modulation of atopic itch
AU - Trier, Anna M.
AU - Kim, Brian S.
N1 - Funding Information:
Work in the Kim laboratory is supported by K08AR065577 and R01AR070116 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH) , the American Skin Association (ASA) , the Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award and LEO Pharma . A.M.T. is supported by T32GM007200 from the National Institute of General Medical Sciences at the NIH . We also thank members of the Kim laboratory for insightful discussions of the manuscript.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Atopic dermatitis (AD) is an inflammatory skin disease characterized by two primary features: relapsing skin lesions and chronic itch. Major advances in our understanding of type 2 immunity have led to new insights into the critical factors that promote the development and persistence of AD-associated skin inflammation. Although inflammation is strongly associated with the development of atopic itch, the precise mechanisms by which itch arises in AD are poorly understood. In this review, we highlight recent studies that have started to unveil how various proinflammatory factors released within the skin can elicit sensations of itch and discuss the therapeutic potential of targeting these neuroimmunologic processes.
AB - Atopic dermatitis (AD) is an inflammatory skin disease characterized by two primary features: relapsing skin lesions and chronic itch. Major advances in our understanding of type 2 immunity have led to new insights into the critical factors that promote the development and persistence of AD-associated skin inflammation. Although inflammation is strongly associated with the development of atopic itch, the precise mechanisms by which itch arises in AD are poorly understood. In this review, we highlight recent studies that have started to unveil how various proinflammatory factors released within the skin can elicit sensations of itch and discuss the therapeutic potential of targeting these neuroimmunologic processes.
UR - http://www.scopus.com/inward/record.url?scp=85048705021&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.05.005
DO - 10.1016/j.coi.2018.05.005
M3 - Review article
C2 - 29935376
AN - SCOPUS:85048705021
SN - 0952-7915
VL - 54
SP - 7
EP - 12
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -